Sarepta Therapeutics, Inc. (SRPT)
NASDAQ$98.37
Market Cap
$9.55B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
72 of 925
Rank in Industry
51 of 528
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
SRPT Insider Trading Activity
SRPT Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $4,955,728 | 1 | 13 |
Sells | $11,061,140 | 7 | 87 |
Related Transactions
| Chambers Michael Andrew | director | 1 | $4.96M | 0 | $0 | $4.96M |
| Boor Kathryn Jean | director | 0 | $0 | 1 | $205,400 | $-205,400 |
| Murray Dallan | Chief Customer Officer | 0 | $0 | 1 | $508,900 | $-508,900 |
| Estepan Ian Michael | Chief Financial Officer | 0 | $0 | 1 | $822,100 | $-822,100 |
| Wigzell Hans Lennart Rudolf | director | 0 | $0 | 1 | $1.31M | $-1.31M |
| Arif Bilal | Chief Tech Ops Officer | 0 | $0 | 2 | $1.92M | $-1.92M |
| Brown Ryan Edward | EVP, General Counsel | 0 | $0 | 1 | $6.3M | $-6.3M |
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 …
Insider Activity of Sarepta Therapeutics, Inc.
Over the last 12 months, insiders at Sarepta Therapeutics, Inc. have bought $4.96M and sold $11.06M worth of Sarepta Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Sarepta Therapeutics, Inc. have bought $6.22M and sold $11.71M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Chambers Michael Andrew (director) — $4.96M.
The last purchase of 37,038 shares for transaction amount of $4.96M was made by Chambers Michael Andrew (director) on 2024‑08‑16.
List of Insider Buy and Sell Transactions, Sarepta Therapeutics, Inc.
| 2024-12-12 | Sale | Wigzell Hans Lennart Rudolf | director | 10,500 0.011% | $124.84 | $1.31M | -6.99% | |
| 2024-12-05 | Sale | Boor Kathryn Jean | director | 1,636 0.0017% | $125.55 | $205,400 | -7.51% | |
| 2024-08-30 | Sale | Estepan Ian Michael | Chief Financial Officer | 5,985 0.0063% | $137.36 | $822,100 | -10.44% | |
| 2024-08-16 | Chambers Michael Andrew | director | 37,038 0.0404% | $133.80 | $4.96M | -7.99% | ||
| 2024-06-25 | Sale | Arif Bilal | Chief Tech Ops Officer | 3,898 0.0043% | $163.23 | $636,271 | -20.99% | |
| 2024-06-25 | Sale | Brown Ryan Edward | EVP, General Counsel | 38,957 0.0421% | $161.61 | $6.3M | -20.99% | |
| 2024-06-24 | Sale | Arif Bilal | Chief Tech Ops Officer | 7,859 0.0083% | $163.08 | $1.28M | -23.74% | |
| 2024-05-02 | Sale | Murray Dallan | Chief Customer Officer | 3,635 0.0041% | $140.00 | $508,900 | -4.30% | |
| 2024-03-11 | Sale | Boor Kathryn Jean | director | 761 0.0008% | $122.93 | $93,550 | +3.09% | |
| 2024-03-08 | Sale | Wigzell Hans Lennart Rudolf | director | 15,000 0.0159% | $123.25 | $1.85M | +0.78% | |
| 2024-03-05 | Sale | Mayo Stephen | director | 3,135 0.0033% | $122.96 | $385,480 | +2.03% | |
| 2024-03-01 | Sale | Estepan Ian Michael | Chief Financial Officer | 1,200 0.0013% | $128.30 | $153,960 | -2.59% | |
| 2024-03-01 | Sale | Brown Ryan Edward | EVP, General Counsel | 2,000 0.0021% | $125.34 | $250,680 | -2.59% | |
| 2024-03-01 | Sale | Arif Bilal | Chief Tech Ops Officer | 2,000 0.0021% | $128.84 | $257,676 | -2.59% | |
| 2023-11-03 | INGRAM DOUGLAS S | President & CEO | 25,225 0.0275% | $79.36 | $2M | +60.46% | ||
| 2023-11-03 | Barry Richard | director | 50,000 0.0542% | $78.81 | $3.94M | +60.46% | ||
| 2023-08-14 | Chambers Michael Andrew | director | 9,979 0.0104% | $109.47 | $1.09M | +7.99% | ||
| 2023-08-11 | Chambers Michael Andrew | director | 23,686 0.0254% | $108.05 | $2.56M | +12.24% | ||
| 2023-08-10 | Chambers Michael Andrew | director | 34,867 0.0374% | $106.15 | $3.7M | +14.36% | ||
| 2023-08-04 | Sale | Wigzell Hans Lennart Rudolf | director | 15,000 0.0163% | $106.72 | $1.6M | +14.59% |
Total: 152
*Gray background shows transactions not older than one year
Insider Historical Profitability
17.85%
| Chambers Michael Andrew | director | 284034 0.2927% | $27.94M | 5 | 0 | +11.57% |
| HAYWOOD GEORGE WEAVER | 8213717 8.4649% | $807.98M | 16 | 0 | <0.0001% | |
| INGRAM DOUGLAS S | President & CEO | 390307 0.4022% | $38.39M | 7 | 0 | +25.87% |
| Barry Richard | director | 140000 0.1443% | $13.77M | 7 | 3 | +30.38% |
| BEHRENS M KATHLEEN | director | 130517 0.1345% | $12.84M | 6 | 2 | +42.52% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$961,890,236 | 276 | 22.46% | $13.1B | |
$211,610,344 | 91 | 38.45% | $7.13B | |
$2,765,836 | 72 | 20.00% | $13.47B | |
$108,876,545 | 67 | 72.81% | $7.52B | |
Sarepta Therapeutics, Inc. (SRPT) | $42,463,802 | 57 | 17.85% | $9.55B |
SRPT Institutional Investors: Active Positions
| Increased Positions | 235 | +45.19% | 10M | +11.11% |
| Decreased Positions | 223 | -42.88% | 7M | -8.46% |
| New Positions | 74 | New | 3M | New |
| Sold Out Positions | 60 | Sold Out | 2M | Sold Out |
| Total Postitions | 532 | +2.31% | 89M | +2.65% |
SRPT Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $1.19M | 11.66% | 11.19M | +168,672 | +1.53% | 2024-12-31 |
| Vanguard Group Inc | $969,872.00 | 9.46% | 9.09M | +117,904 | +1.31% | 2024-12-31 |
| Capital International Investors | $928,419.00 | 9.06% | 8.7M | +2M | +38.95% | 2024-12-31 |
| Janus Henderson Group Plc | $462,048.00 | 4.51% | 4.33M | -30,188 | -0.69% | 2024-12-31 |
| State Street Corp | $434,458.00 | 4.24% | 4.07M | -200,902 | -4.7% | 2024-12-31 |
| Farallon Capital Management Llc | $305,849.00 | 2.98% | 2.87M | +285,100 | +11.05% | 2024-12-31 |
| Avoro Capital Advisors Llc | $272,805.00 | 2.66% | 2.56M | 0 | 0% | 2024-12-31 |
| Bank Of New York Mellon Corp | $229,030.00 | 2.24% | 2.15M | +26,581 | +1.25% | 2024-12-31 |
| Wellington Management Group Llp | $220,841.00 | 2.16% | 2.07M | -657,842 | -24.13% | 2024-12-31 |
| Jpmorgan Chase & Co | $215,699.00 | 2.11% | 2.02M | -178,279 | -8.11% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.